Stockholders’ Equity

The Company recognizes stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation--Stock Compensation. Stock-based compensation expense, excluding compensation charges related to our employee stock purchase plan, or the ESPP, was $4,099 and $3,267 for the year ended December 31, 2019 and 2018, respectively.

The Company is authorized to grant stock options, restricted stock awards and other stock-based awards under its 2016 Equity and Incentive Plan (the 2016 Plan) with respect to up to 3,000 shares of common stock (plus up to an additional 1,690 shares in respect of certain awards under earlier equity compensation plans that may be forfeited, canceled, reacquired by the Company or terminated after adoption of the 2016 Plan). Options have generally been granted with an exercise price equal to the fair market value of the common stock on the date of grant and have generally provided for vesting in equal annual amounts over four years beginning on the first anniversary of the date of the grant. No options are exercisable for periods of more than five years after date of grant. Under the 2016 Plan, each share issued under awards other than options and stock appreciation rights will reduce the number of shares reserved for issuance by two shares. Shares issued under options or stock appreciation rights will reduce the shares reserved for issuance on a share-for-share basis. The 2016 Plan and earlier equity compensation plans, pursuant to which an aggregate of 12,415 shares of the Company’s common stock were reserved for issuance, were all approved by the Company's shareholders. As of December 31, 2019, 402 shares were available for future grants. The Compensation Committee of the Board of Directors administers the equity compensation plans, approves the individuals to whom awards will be granted and determines the number of shares and other terms of each award. Outstanding options under the Company's equity compensation plans at December 31, 2019 expire from January 2020 through August 2024. None of the Company’s outstanding options includes performance-based or market-based vesting conditions as of December 31, 2019.


(a)	Employee Stock Options

The Company has estimated the fair value of each option grant on the date of grant using the Black-Scholes option-pricing model. The expected volatility assumption is based on the historical daily price data of the Company’s common stock over a period equivalent to the weighted average expected life of the Company’s options. The expected term of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time the options granted are expected to be outstanding. The risk-free interest rate is based on the actual U.S. Treasury zero-coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend yield of zero is based upon the fact that the Company has not historically declared or paid cash dividends, and does not expect to declare or pay dividends in the foreseeable future.

The per share weighted-average fair values of stock options granted during 2019 and 2018 were $3.09 and $3.82, respectively. The weighted-average assumptions used to value options as of their grant date were as follows:



	Year Ended December 31,
	2019		2018
Risk-free interest rate	1.91	%	2.81	%
Expected volatility	36.9	%	36.6	%
Expected life (in years)	4.27		4.29
Dividend yield	0	%	0	%

The changes in outstanding stock options for the year ended December 31, 2019 and 2018 are as follows:



	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2018	1,276		$	10.28
Granted	630		$	9.48
Exercised	(37	)	$	7.89
Expired, canceled or forfeited	(245	)	$	11.35
Outstanding at December 31, 2019	1,624		$	9.86	3.25	$	2,325
Exercisable at December 31, 2019	440		$	10.26	2.07	$	572
Options vested or expected to vest at December 31, 2019	1,624		$	9.86	3.25	$	2,325



	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2017	1,064		$	10.06
Granted	404		$	11.30
Exercised	(40	)	$	7.93
Expired, canceled or forfeited	(152	)	$	12.14
Outstanding at December 31, 2018	1,276		$	10.28	3.15	$	1,078
Exercisable at December 31, 2018	379		$	10.98	1.68	$	211
Options vested or expected to vest at December 31, 2018	1,276		$	10.28	3.15	$	1,078

The total aggregate intrinsic value of options exercised was $108 and $163 in 2019 and 2018, respectively.

As of December 31, 2019, there was $3,032 of total unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.65 years. In 2019 and 2018, the Company recorded compensation charges of $1,076 and $856, respectively, related to stock options. Compensation costs for options subject only to service conditions that vest ratably are recognized on a straight-line basis over the requisite service period for the entire award. During 2019 and 2018, cash received under stock option plans for exercises was $286 and $317, respectively.


(b)	Restricted Stock

The Company granted 322 and 200 restricted stock awards to employees under the terms of the 2016 Plan or the Amended and Restated 2006 Stock Incentive Plan (2006 Plan) for the years ended December 31, 2019 and 2018, respectively. The restricted stock awards have generally provided for vesting annually over four years from the date of grant subject to the recipient remaining an employee through the applicable vesting dates. Compensation expense for restricted stock awards is measured at fair value on the date of grant based on the number of shares granted and the quoted market closing price of the Company’s common stock. Such value is recognized as expense over the vesting period of the award, net of forfeitures. The weighted-average grant-date fair value of restricted stock granted during 2019 and 2018 was $9.67 and $11.47 per share, respectively.

As of December 31, 2019, there was $3,350 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 2.14 years. Compensation costs for awards subject only to service conditions that vest ratably are recognized on a straight-line basis over the requisite service period for the entire award. Compensation cost for awards initially subject to certain performance conditions are recognized on a ratable basis over the requisite service period for the entire award. In 2019 and 2018, the Company recorded compensation charges of $3,023 and $2,411, respectively, related to restricted stock awards.

Restricted stock activity under the 2006 Plan and the 2016 Plan for 2019 is as follows:



	Number of Shares		Weighted- average grant date fair value
Outstanding at December 31, 2018, unvested	526		$	9.86
Granted	322		9.67
Vested	(319	)	10.24
Forfeited	(31	)	9.54
Outstanding at December 31, 2019, unvested	498		$	9.51


(c)	Employee Stock Purchase Plan

Under the Company's Amended and Restated 1996 Employee Stock Purchase Plan (ESPP), an aggregate of 1,650 shares of common stock have been reserved for issuance, of which 891 shares remain available as of December 31, 2019.

The ESPP covers all of the Company’s employees. Under the terms of the ESPP, eligible employees can elect to have up to six percent of their pre-tax compensation withheld to purchase shares of the Company’s common stock on a semi-annual basis at 85% of the market price on the first or last day of each purchase period, whichever is lower. During 2019 and 2018, shares issued under this plan were 45 and 17 shares, respectively. The Company utilizes the Black-Scholes option-pricing model to calculate the fair value of these discounted purchases. The fair value of the 15% discount is recognized as compensation expense over the purchase period. The Company applies a graded vesting approach because the ESPP provides for multiple purchase periods and is, in substance, a series of linked awards. In 2019 and 2018, the Company recorded compensation charges of $60 and $54, respectively, related to the ESPP. During 2019 and 2018, cash received under the ESPP was $414 and $167, respectively.


(d)	Stock-Based Compensation Expense

The following presents stock-based compensation expense, including expense for the ESPP, in the Company's consolidated statements of operations for the years ended December 31, 2019 and 2018.



	2019		2018
Cost of product sales	$	240	$	163
Cost of service sales	—		—
Research and development	815		672
Sales, marketing and support	867		663
General and administrative	2,237		1,823
	$	4,159	$	3,321

(e) Accumulated Other Comprehensive Loss (AOCI)

Comprehensive income (loss) includes net income (loss), unrealized gains and losses from foreign currency translation, and unrealized gains and losses from available for sale marketable securities and changes in fair value related to interest rate swap derivative instruments, net of tax attributes, which were not material. The components of the Company’s comprehensive income (loss) and the effect on earnings for the periods presented are detailed in the accompanying consolidated statements of comprehensive income (loss).



	Foreign Currency Translation			Unrealized (Loss) Gain on Available for Sale Marketable Securities			Interest Rate Swaps			Total Accumulated Other Comprehensive Loss
Balance, December 31, 2017	$	(11,247	)	$	(1	)	$	(69	)	$	(11,317	)
Other comprehensive (loss) income before reclassifications	(3,473		)	1			10			(3,462		)
Reclassified from AOCI	—			—			48			48
Net other comprehensive (loss) income, December 31, 2018	(3,473		)	1			58			(3,414		)
Balance, December 31, 2018	(14,720		)	—			(11		)	(14,731		)
Other comprehensive income before reclassifications	470			—			3			473
Reclassified from AOCI	11,483			—			8			11,491
Net other comprehensive income, December 31, 2019	11,953			—			11			11,964
Balance, December 31, 2019	$	(2,767	)	$	—		$	—		$	(2,767	)

For additional information, see Note 2, "Marketable Securities", and see Note 15, "Derivative Instruments and Hedging Activities."